Search

Your search keyword '"Westervelt, Peter"' showing total 1,296 results

Search Constraints

Start Over You searched for: Author "Westervelt, Peter" Remove constraint Author: "Westervelt, Peter"
1,296 results on '"Westervelt, Peter"'

Search Results

201. Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas

202. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

203. The Immune Landscape of Cancer

204. A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples

205. Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types

206. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers

207. Pathogenic Germline Variants in 10,389 Adult Cancers

208. An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

209. Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas

210. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

211. Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow

212. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant

215. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

218. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

219. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti–T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease–Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation

220. Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML

221. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

222. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

224. Phase I/II Study of Intravenous Plerixafor Added to a Mobilization Regimen of Granulocyte Colony–Stimulating Factor in Lymphoma Patients Undergoing Autologous Stem Cell Collection

226. Fresh or Cryopreserved CD34 + -Selected Mobilized Peripheral Blood Stem and Progenitor Cells for the Treatment of Poor Graft Function after Allogeneic Hematopoietic Cell Transplantation

227. The effect of donor source on outcomes after second allogeneic hematopoietic cell transplantation for relapsed leukemia.

228. Mobilization of allogeneic peripheral blood stem cell donors with intravenous plerixafor mobilizes a unique graft

229. T Cell–Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia

231. Outcomes after Second Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

233. T-Cell Replete Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Results in Outcomes Similar to Those of Traditionally Matched Donors in Active Acute Myeloid Leukemia

234. Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial

235. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression

236. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001

237. Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology

240. Dynamic Changes in MDS Clonal Architecture Following Allogeneic Stem Cell Transplant

242. Risk Factors for the Development of and Outcomes of Patients Who Develop Severe Cytokine Release Syndrome after Peripheral Blood Haploidentical Donor Transplant

243. Post-Transplant Outcomes in AML Patients ≥ 60 Years of Age Beyond CR1

245. Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation

246. A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti- T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT)

250. DNMT3A-Dependent DNA Methylation May Act As a Tumor Suppressor-Not a Tumor Promoter-during AML Progression

Catalog

Books, media, physical & digital resources